William Blair Brokers Reduce Earnings Estimates for Repligen

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at William Blair dropped their Q1 2025 earnings per share estimates for Repligen in a research report issued on Monday, March 10th. William Blair analyst M. Larew now anticipates that the biotechnology company will earn $0.32 per share for the quarter, down from their prior forecast of $0.33. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2025 earnings at $0.42 EPS, FY2025 earnings at $1.67 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.30 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%.

RGEN has been the subject of a number of other research reports. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Finally, Royal Bank of Canada increased their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Trading Up 7.4 %

Shares of NASDAQ:RGEN opened at $147.13 on Tuesday. The company has a market cap of $8.24 billion, a P/E ratio of -288.49, a PEG ratio of 4.54 and a beta of 0.95. Repligen has a 1 year low of $113.50 and a 1 year high of $200.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s fifty day moving average price is $157.16 and its 200-day moving average price is $148.52.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its stake in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Vanguard Group Inc. grew its position in Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC grew its position in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. grew its position in Repligen by 23.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC grew its position in Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after purchasing an additional 6,872 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.